PF-Atlas › Drugs › nintedanib

nintedanib

Idiopathic Pulmonary Fibrosis

Clinical trials

Developer

Boehringer Ingelheim

Overview

nintedanib is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 34 tracked IPF clinical trials.

nintedanib clinical trials

NCT02606877 (Phase 4)NCT02598193 (Phase 4)NCT02579603 (Phase 4)NCT02597933 (Phase 3)NCT02999178 (Phase 3)NCT02607722 (Not specified)NCT05799755 (Phase 4)NCT02230982 (Not specified)NCT03047031 (Not specified)NCT05065190 (Phase 3)NCT06200714 (Not specified)NCT01619085 (Phase 3)

Explore related

All trials Research

Medical disclaimer. This page summarizes research about nintedanib for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.